Medicus Pharma (NASDAQ:MDCX) Stock Rating Lowered by Wall Street Zen

Medicus Pharma (NASDAQ:MDCX) was downgraded by investment analysts at Wall Street Zen to a “strong sell” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Other equities analysts have also recently issued research reports about the company. Alliance Global Partners reissued a “buy” rating on shares of Medicus Pharma in a report on Monday, September 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Medicus Pharma in a report on Friday, October 2nd. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Medicus Pharma presently has an average rating of “Moderate Buy” and a consensus target price of $450.00.

Medicus Pharma Price Performance

NASDAQ MDCX opened at $3.25 on Friday. The company has a market capitalization of $4.09 million, a PE ratio of -0.03 and a beta of 0.30. The company has a fifty day moving average of $9.65 and a 200 day moving average of $15.05. Medicus Pharma has a 1 year low of $2.92 and a 1 year high of $139.00.

Medicus Pharma (NASDAQ:MDCX) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($10.50) EPS for the quarter, missing the consensus estimate of ($6.38) by ($4.12). Research analysts expect that Medicus Pharma will post -36.25 earnings per share for the current year.

Hedge Funds Weigh In On Medicus Pharma

An institutional investor recently bought a new position in Medicus Pharma stock. Sterling Investment Advisors Ltd. bought a new stake in shares of Medicus Pharma Ltd (NASDAQ:MDCX) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 100,000 shares of the company’s stock, valued at approximately $45,000. Sterling Investment Advisors Ltd. owned about 0.16% of Medicus Pharma at the end of the most recent reporting period.

Medicus Pharma Company Profile

Medicus Pharma Ltd. is a life sciences company focused on acquiring, developing and commercializing innovative therapeutic and medical device technologies. Its activities are centered primarily on wound care, dermatology and related areas of medical treatment.

The company’s portfolio includes Natrox® Oxygen Wound Therapy, a device designed to deliver continuous topical oxygen to the wound site. The technology is intended to support the treatment of chronic and hard-to-heal wounds and may be used in clinical and home-care settings, subject to applicable regulatory approvals.

Medicus Pharma serves healthcare markets through the commercialization of its technologies and partnerships with medical professionals and distribution networks.